COVID-19：出现了有关疫苗方法的问题：强生阿斯利康（J＆J AstraZeneca）试验悬浮液
-两个主要候选人的共同事项-
强生和阿斯特拉Zeneca疫苗均基于腺病毒
腺病毒载体的测试已成功，但并非全部
疫苗的重要共同点：
由于可能的副作用，两种COVID 19疫苗已终止临床试验。
实际上，有一个重要的共同点。
两者均基于腺病毒。
约翰逊·恩德·约翰逊（J＆J）
10月12日下旬，由于无法解释的症状，受试者宣布暂停研究。
英国的阿斯特拉（Astra Zeneca）：
牛津大学正在开发疫苗。
在美国进行的一项研究中，两名受试者出现了神经系统症状，并被中断了一个多月。
Moderna和Pfizer Biontech：
在阿斯特拉·塞内卡（Astra Zeneca）休战期间，Moderna和Physer-Biontech Coalition领导了疫苗开发竞赛。
彭博社
https://www.bloomberg.co.jp/news/articles/2020-10-19/QIEFJVDWLU6T01
Covid-19 Vaccines: Adenoviruses and Coronavirus Latest Research News and Updates
Experimental shots from J&J, AstraZeneca based on adenoviruses
Past experiments with vectors include successes, failures
Two Covid-19 vaccines stalled by potential side effects have one key feature in common:
Both are based on adenoviruses,
cold germs that researchers have used in experimental therapies for decades with varying results.
Johnson & Johnson said late Monday
it would pause its trial to investigate an illness, which it didn’t specify, in a study participant.
Meanwhile,
AstraZeneca Plc’s U.S. trial of the vaccine
it’s developing with the University of Oxford has been halted by regulators for more than a month after neurological symptoms arose in two volunteers.
With AstraZeneca in a pit stop,
vaccines from Moderna Inc. and the Pfizer Inc.-BioNTech SE partnership have taken the lead in the race to be first out with a shot.
Bloomberg